RIPK1 and Parkinson disease: Similarly, genetic ablation of RIPK3 or pharmacological inhibition of RIPK1 in the 6-OHDA-induced PD mouse model has been found to decrease dopaminergic neuron degeneration and improve motor performance [20, 40].